News Releases

Updated Clinical Data from Combination of X4P-001-IO and Inlyta ®  (axitinib) in Patients with Clear Cell Renal Cell Carcinoma Will Be Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics CAMBRIDGE, Mass., October 25, 2017  – X4 Ph...

Combination of CXCR4 inhibition plus Inlyta ®  was generally well tolerated Phase 1 dose escalation completed and enrollment in Phase 2 expansion continues CAMBRIDGE, Mass., Sept. 11, 2017  – X4 Pharmaceuticals, a clinical stage biotechnology company developing a novel CXCR4 inhi...

CAMBRIDGE, Mass., August 31, 2017  –  X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases, today announced that the European Society of Medical Oncology has publishe...

Multi-Year Research Plan to Investigate Mechanisms of Aberrant Immune Function  in a Genetic Model of WHIM Syndrome CAMBRIDGE, Mass., August 2, 2017  – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell traffic...

Phase 2 dose of X4P-001   in combination with Inlyta ®  selected from ongoing Phase 1/2 study CAMBRIDGE, Mass., May 25, 2017  –  X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer an...

CAMBRIDGE, Mass., March 29, 2017  – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that Paula Ragan, PhD, President and Chief Executive Officer,...

CAMBRIDGE, Mass., March 1, 2017  – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that Paula Ragan, PhD, President and Chief Executive Officer, ...

CAMBRIDGE, Mass., January 30, 2017  –  X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced the initiation of a Phase 2/3 study with the first patient...

Clinical program now includes two Phase 1/2 studies in ccRCC to assess X4P-001 in combination with approved therapies CAMBRIDGE, Mass .,  January 26, 2017  –   X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell...

Experienced Medical Leader in Innovative Drug Development to Guide Clinical Programs in Immuno-Oncology and Rare Diseases CAMBRIDGE, Mass., January 23, 2017  – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell...

Preclinical data demonstrate mechanism of X4P-001 in renal cell carcinoma combination regimen CAMBRIDGE, Mass., November 30, 2016  – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking and increase t...

...

News  ...

CAMBRIDGE, Mass., September 7, 2016  – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking and increase the ability for T-cells to track and destroy cancer, today announced that Paula Ragan, PhD, Pre...

CAMBRIDGE, Mass., August 11, 2016  – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking and increase the ability for T-cells to track and destroy cancer, today announced that Paula Ragan, PhD, Presi...

CAMBRIDGE, Mass., May 9, 2016  – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking and increase the ability for T-cells to track and destroy cancer, today announced dosing of the first patient in a...

Preclinical data demonstrated synergistic anti-tumor activity of X4P-001 in combination with VEGF inhibitor in preclinical models of renal cell carcinoma CAMBRIDGE, Mass., April 19, 2016  – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibito...

...

Experts in cancer drug development to advise on corporate strategy and product development Cambridge, Mass., April 4, 2016  – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking and increase the abil...

CXCR4 inhibitor offers novel immuno-oncology and anti-angiogenic approach to the treatment of ccRCC Cambridge, Mass. – December 14, 2015  – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking and inc...